Literature DB >> 25643026

Allopregnanolone association with psychophysiological and cognitive functions during acute smoking abstinence in premenopausal women.

Alicia M Allen1, Mustafa al'Absi2, Harry Lando1, Sharon S Allen1.   

Abstract

Nicotine response may predict susceptibility to smoking relapse. Allopregnanolone, a neuroactive steroid metabolized from progesterone, has been shown to be associated with several symptoms of nicotine response. We sought to explore the association between allopregnanolone and response to nicotine during acute smoking abstinence in premenopausal women. Participants completed 2 nicotine-response laboratory sessions, 1 in their follicular (low allopregnanolone) and 1 in their luteal (high allopregnanolone) menstrual phase, on the fourth day of biochemically confirmed smoking abstinence. During the laboratory sessions, participants self-administered a nicotine nasal spray and completed a timed series of cardiovascular, cognitive, and subjective assessments of response to nicotine. The relationships of allopregnanolone with baseline values and change scores of outcome measures were assessed using covariance pattern modeling. Study participants (N = 77) had a mean age of 29.9 (SD = 6.8) years and smoked an average of 12.2 (SD = 4.9) cigarettes per day. Allopregnanolone concentration measured before nicotine administration was positively associated with systolic (β = 0.85, p = .04) and diastolic blood pressure (β = 1.19, p < .001) and self-report of physical symptoms (β = 0.58, p < .001), dizziness (β = 0.88, p < .01), jitteriness (β = 0.90, p = .04), and pleasantness (β = 2.05, p = .04). Allopregnanolone also had significant positive associations with change in cognition following nicotine nasal spray administration, specifically discriminability as a measure of attention (β = 1.15, p = .05) and response bias as a measure of impulsivity (β = 0.13, p = .02). These data suggest that allopregnanolone may be related to cardiovascular and subjective physical state during acute smoking abstinence, as well as cognitive response to nicotine. PsycINFO Database Record (c) 2015 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25643026      PMCID: PMC4394732          DOI: 10.1037/a0038747

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  27 in total

1.  Psychomotor function and psychoactive drugs. 1980.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 2.  Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems.

Authors:  Vita Birzniece; Torbjörn Bäckström; Inga-Maj Johansson; Charlotte Lindblad; Per Lundgren; Magnus Löfgren; Tommy Olsson; Gianna Ragagnin; Magdalena Taube; Sahruh Turkmen; Göran Wahlström; Ming-De Wang; Anna-Carin Wihlbäck; Di Zhu
Journal:  Brain Res Rev       Date:  2005-12-20

3.  Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers.

Authors:  H E Jones; B E Garrett; R R Griffiths
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

4.  Individual differences in the subjective effects of the first cigarette of the day: a self-report method for studying tolerance.

Authors:  J L Pillitteri; L T Kozlowski; C T Sweeney; T F Heatherton
Journal:  Exp Clin Psychopharmacol       Date:  1997-02       Impact factor: 3.157

5.  The Walter Reed performance assessment battery.

Authors:  D R Thorne; S G Genser; H C Sing; F W Hegge
Journal:  Neurobehav Toxicol Teratol       Date:  1985 Jul-Aug

6.  Histories of depression, allopregnanolone responses to stress, and premenstrual symptoms in women.

Authors:  Rebecca R Klatzkin; A Leslie Morrow; Kathleen C Light; Cort A Pedersen; Susan S Girdler
Journal:  Biol Psychol       Date:  2005-06-13       Impact factor: 3.251

7.  Effects of menstrual phase on reactivity to nicotine.

Authors:  J L Marks; C S Pomerleau; O F Pomerleau
Journal:  Addict Behav       Date:  1999 Jan-Feb       Impact factor: 3.913

8.  Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers.

Authors:  Christine E Marx; William T Trost; Lawrence Shampine; Frederique M Behm; Louis A Giordano; Mark W Massing; Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2006-01-10       Impact factor: 4.530

9.  Comparison of tests used to distinguish smokers from nonsmokers.

Authors:  M J Jarvis; H Tunstall-Pedoe; C Feyerabend; C Vesey; Y Saloojee
Journal:  Am J Public Health       Date:  1987-11       Impact factor: 9.308

Review 10.  Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence.

Authors:  O F Pomerleau
Journal:  Behav Genet       Date:  1995-03       Impact factor: 2.805

View more
  5 in total

Review 1.  Clinical Potential of Neurosteroids for CNS Disorders.

Authors:  Doodipala Samba Reddy; William A Estes
Journal:  Trends Pharmacol Sci       Date:  2016-05-05       Impact factor: 14.819

2.  Subjective response to intranasal nicotine administration in oral contraceptive users and naturally-cycling women.

Authors:  Alicia M Allen; Samantha C Friedrichsen; Nicole Petersen; Sharon S Allen
Journal:  Addict Behav       Date:  2019-07-03       Impact factor: 3.913

3.  Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial.

Authors:  Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen
Journal:  Addiction       Date:  2019-06-17       Impact factor: 6.526

Review 4.  Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review.

Authors:  MacKenzie R Peltier; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

5.  Ovarian hormones, menstrual cycle phase, and smoking: a review with recommendations for future studies.

Authors:  Reagan R Wetherill; Teresa R Franklin; Sharon S Allen
Journal:  Curr Addict Rep       Date:  2016-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.